Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evolent Health ( (EVH) ) just unveiled an update.
On August 19, 2025, Evolent Health announced the pricing and upsize of its offering of $145 million in 4.50% convertible senior notes due 2031, with an option for purchasers to buy an additional $21.75 million. The proceeds will be used to repurchase $167.4 million of its 1.50% convertible senior notes due 2025 and $40 million worth of Class A common stock. This financial maneuver aims to reduce interest expenses and manage debt maturities, with implications for shareholder value and market activity.
The most recent analyst rating on (EVH) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.
Spark’s Take on EVH Stock
According to Spark, TipRanks’ AI Analyst, EVH is a Neutral.
Evolent Health’s overall stock score reflects significant challenges in financial performance and valuation, with ongoing losses and a bearish technical outlook. However, the positive sentiment from the earnings call, driven by strong EBITDA performance and new partnerships, provides some optimism for future growth. The company’s efforts to improve cash flow and leverage are also noted, but operational efficiency and profitability remain key areas for improvement.
To see Spark’s full report on EVH stock, click here.
More about Evolent Health
Evolent Health, Inc. specializes in achieving better health outcomes for people with complex conditions by providing solutions that simplify and reduce the cost of healthcare. The company serves a national base of leading payers and providers and is recognized as a top workplace in the healthcare industry.
Average Trading Volume: 2,708,834
Technical Sentiment Signal: Sell
Current Market Cap: $1.09B
Learn more about EVH stock on TipRanks’ Stock Analysis page.